Interestingly, we found that BAY11-7082 treatment resulted in immunogenic cell death (ICD) as revealed by overexpression of Calreticulin, HSP70, HMGB1 and ATP in treated cells [44] (Fig. 5D–F and Additional file 4: Figure S7F, G), suggesting that BAY11-7082 compound could activate antigen presenting cells and immunologically synergized with KRAS inhibitors for treating K-sgZNF24 lung cancers [45]. The gene discussed is HMGB1; the disease is lung carcinoma.